OM
PRAX icon

Opaleye Management’s Praxis Precision Medicines PRAX Stock Holding History

Opaleye Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,228
Closed -$3.49M – 64
2020
Q4 		$3.49M Buy
+4,228
New +$2.47M 0.46% 44

Other funds holding PRAX

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Opaleye Management's PRAX Position: Q1 2021 in Review

Opaleye Management sold out of Praxis Precision Medicines (PRAX) in Q1 2021, closing a stake of 4,228 shares — an estimated $3.49M sold.

Opaleye Management first reported a position in PRAX in Q4 2020 and held it in 1 quarter. The position peaked at $3.49M in Q4 2020. 68 funds tracked by Wall St. Rank hold PRAX as of Q1 2021.

  • Opaleye Management reported no remaining Praxis Precision Medicines position as of Q1 2021 after selling out during the quarter.
  • Opaleye Management sold 4,228 Praxis Precision Medicines shares in Q1 2021, an estimated $3.49M.
  • Opaleye Management first reported a position in Praxis Precision Medicines in Q4 2020 and held it in 1 quarter.
  • Opaleye Management's Praxis Precision Medicines position peaked at $3.49M in Q4 2020.
  • 68 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2021.

Based on Opaleye Management's 13F filing for Q1 2021, filed 18 May 2021.